{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:06:31Z","timestamp":1788919591864,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"name":"Sciensan","award":["SC_045"],"award-info":[{"award-number":["SC_045"]}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"crossref","award":["1SDN2524N"],"award-info":[{"award-number":["1SDN2524N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To characterize real-world COVID-19 vaccine-induced protection, we assessed breakthrough infections and protective antibody thresholds among fully vaccinated nursing home residents (NHR) and staff (NHS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cohort study to assess infection rates and risk factors of symptomatic breakthrough infections in 1605 NHR and 1200 NHS (2021) and 483 NHR (2022) in Belgium using multivariable Cox proportional hazards models adjusted for potential confounders. Additionally, a case-control analysis was used to compare pre-infection and peak vaccine response antibody levels between breakthrough cases and matched controls. Receiver Operating Characteristic (ROC) and net benefit models were fitted to evaluate the protective antibody thresholds in clinical decision making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2021, breakthrough infection incidence was 10.7 (95%CI 8.6\u201313.2) per 100 person-years in NHS and 2.4 (95%CI 1.59\u20133.46) in NHR. This rose to 10.6 (95%CI 8.3\u201313.3) in NHR in 2022. Prior infection was protective in NHS (hazard ratio (HR) 0.25, 95%CI 0.13\u20130.46) and NHR (HR 0.2, 95%CI 0.05\u20130.87). In NHS, younger age (HR 1.02, 95%CI 1.01\u20131.04) and Delta circulation (HR 9.52, 95%CI 2.65\u201334.21) and in NHR, Omicron BA.5 circulation (HR 17.95, 95%CI 2.35-137.13) increased infection risk. Breakthrough cases had lower pre-infection and peak vaccine antibody levels than controls. Protective antibody thresholds were identified and were higher for infections during Omicron than Delta. Using these antibody thresholds to guide vaccination adds value at low risk thresholds, though net benefits were modest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Breakthrough infections affected a minority of vaccinated NHR and NHS. Risk depended on age, prior infection, and circulating variants. Lower antibody levels in cases support their protective role, though thresholds are variant-specific. Our findings support tailored vaccine strategies in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13690-026-01939-7","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:07:30Z","timestamp":1782306450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 breakthrough infection incidence, risk factors, and antibody correlates in Belgian nursing homes residents and staff (2021\u20132022)"],"prefix":"10.1186","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0111-9508","authenticated-orcid":false,"given":"Liselore","family":"De Rop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-9548","authenticated-orcid":false,"given":"Eline","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1430-2327","authenticated-orcid":false,"given":"Natalja","family":"Van Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-6504","authenticated-orcid":false,"given":"Tine","family":"De Burghgraeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5317-7788","authenticated-orcid":false,"given":"Marina","family":"Digregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Coen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-615X","authenticated-orcid":false,"given":"La\u00ebtitia","family":"Buret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-8052","authenticated-orcid":false,"given":"Samuel","family":"Coenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3345-7616","authenticated-orcid":false,"given":"Els","family":"Duysburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5274-822X","authenticated-orcid":false,"given":"Beatrice","family":"Scholtes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-5307","authenticated-orcid":false,"given":"Piet","family":"Cools","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-4987","authenticated-orcid":false,"given":"Stefan","family":"Heytens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-7211","authenticated-orcid":false,"given":"Jan Y","family":"Verbakel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"1939_CR1","unstructured":"Peeters IV, Bustos Sierra M, Renard N, Van der Heyden F, Scohy J et al. A.;. Surveillance of COVID-19 mortality in Belgium, epidemiology and methodology during 1 st and 2 nd wave (March 2020\u201314 February 2021). 2021. Report No.: D\/2021\/14.440\/57."},{"key":"1939_CR2","unstructured":"Catteau L, Haarhuis F, Dequeker S, Vandael E, Stouten V, Litzroth A, Wyndham TC. Surveillance van de COVID-19 vaccinatie in Belgische woonzorgcentra. Resultaten tot 24 maart 2021. Brussel, Belgi\u00eb: Sciensano; 2021. Contract No.: D\/2021\/14.440\/32."},{"issue":"2","key":"1939_CR3","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2666-7568(20)30011-8","volume":"1","author":"LS Cox","year":"2020","unstructured":"Cox LS, Bellantuono I, Lord JM, Sapey E, Mannick JB, Partridge L, Gordon AL, Steves CJ, Witham MD. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. Lancet Healthy Longev. 2020;1(2):e55\u20137. https:\/\/doi.org\/10.1016\/S2666-7568(20)30011-8.","journal-title":"Lancet Healthy Longev"},{"key":"1939_CR4","doi-asserted-by":"publisher","first-page":"126865","DOI":"10.1016\/j.vaccine.2025.126865","volume":"51","author":"E Meyers","year":"2025","unstructured":"Meyers E, De Rop L, Deschepper E, Duysburgh E, De Burghgraeve T, Van Ngoc P, Digregorio M, Coen A, De Clercq N, Wallaert S, et al. SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021. Vaccine. 2025;51:126865. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126865.","journal-title":"Vaccine"},{"key":"1939_CR5","doi-asserted-by":"publisher","unstructured":"Stouten V, Hubin P, Haarhuis F, van Loenhout JAF, Billuart M, Brondeel R, Braeye T, Van Oyen H, Wyndham-Thomas C, Catteau L. Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium. Viruses. 2022;14(4). https:\/\/doi.org\/10.3390\/v14040802.","DOI":"10.3390\/v14040802"},{"issue":"16","key":"1939_CR6","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Levin Einav G, Rubin C, Indenbaum V, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021;385(16):1474\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2109072.","journal-title":"N Engl J Med"},{"key":"1939_CR7","doi-asserted-by":"publisher","unstructured":"Gillot C, Bayart J-L, Closset M, Cabo J, Maloteau V, Dogn\u00e9 J-M, Douxfils J, Favresse J. Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. 2023;61(9):1670\u20135. https:\/\/doi.org\/10.1515\/cclm-2023-0134.","DOI":"10.1515\/cclm-2023-0134"},{"issue":"1","key":"1939_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev. 2022;310(1):6\u201326. https:\/\/doi.org\/10.1111\/imr.13091.","journal-title":"Immunol Rev"},{"key":"1939_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2023.08.002","volume":"262","author":"S Alp \u00c7avu\u015f","year":"2023","unstructured":"Alp \u00c7avu\u015f S, \u00c7elik M, S\u00fcner AF, G\u00fczel I, Irmak \u00c7, \u00c7a\u011flayan D, \u00d6zt\u00fcrk HG, \u015eiyve N, Appak \u00d6, I\u015f\u0131k E, et al. Pre-infection antibody levels of vaccinated healthcare workers with SARS-CoV-2 breakthrough infection: A nested case-control study. Immunol Lett. 2023;262:1\u20136. https:\/\/doi.org\/10.1016\/j.imlet.2023.08.002.","journal-title":"Immunol Lett"},{"issue":"3","key":"1939_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/infdis\/jiac403","volume":"227","author":"M Asamoah-Boaheng","year":"2023","unstructured":"Asamoah-Boaheng M, Goldfarb DM, Karim ME, O\u2019Brien SF, Wall N, Drews SJ, Barakauskas V, Jassem AN, Grunau B. The Relationship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough COVID-19 Among Fully Vaccinated Adults. J Infect Dis. 2023;227(3):339\u201343. https:\/\/doi.org\/10.1093\/infdis\/jiac403.","journal-title":"J Infect Dis"},{"issue":"5","key":"1939_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ajt.2023.02.015","volume":"23","author":"D Kemlin","year":"2023","unstructured":"Kemlin D, Gemander N, Depick\u00e8re S, Olislagers V, Georges D, Waegemans A, Pannus P, Lemy A, Goossens ME, Desombere I, et al. Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients. Am J Transpl. 2023;23(5):649\u201358. https:\/\/doi.org\/10.1016\/j.ajt.2023.02.015.","journal-title":"Am J Transpl"},{"issue":"5","key":"1939_CR12","doi-asserted-by":"publisher","first-page":"e02026","DOI":"10.1128\/spectrum.02026-22","volume":"10","author":"C McGee","year":"2022","unstructured":"McGee C, Shi M, House J, Drude A, Gonzalez G, Martin N, Chen S-H, Rogers H, Njunge A, Hodge X, et al. Longitudinal Serological Surveillance for COVID-19 Antibodies after Infection and Vaccination. Microbiol Spectr. 2022;10(5):e02026\u201322. https:\/\/doi.org\/10.1128\/spectrum.02026-22.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"1939_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/joim.13471","volume":"292","author":"DK Sanghavi","year":"2022","unstructured":"Sanghavi DK, Bhakta S, Wadei HM, Bosch W, Cowart JB, Carter RE, Shah SZ, Pollock BD, Neville MR, Oman SP, et al. Low antispike antibody levels correlate with poor outcomes in COVID-19 breakthrough hospitalizations. J Intern Med. 2022;292(1):127\u201335. https:\/\/doi.org\/10.1111\/joim.13471.","journal-title":"J Intern Med"},{"issue":"1","key":"1939_CR14","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1080\/22221751.2022.2065936","volume":"11","author":"SL Yang","year":"2022","unstructured":"Yang SL, Mat Ripen A, Leong CT, Lee JV, Yen CH, Chand AK, Koh K, Abdul Rahim NAB, Gokilavanan V, Mohamed NN. COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia. Emerg Microbes Infections. 2022;11(1):1262\u201371. https:\/\/doi.org\/10.1080\/22221751.2022.2065936.\u00a0","journal-title":"Emerg Microbes Infections"},{"key":"1939_CR15","doi-asserted-by":"publisher","unstructured":"Meyers E, Deschepper E, Duysburgh E, De Rop L, De Burghgraeve T, Van Ngoc P, Digregorio M, Delogne S, Coen A, De Clercq N, et al. Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study. Viruses. 2022;14(11). https:\/\/doi.org\/10.3390\/v14112361.","DOI":"10.3390\/v14112361"},{"issue":"2","key":"1939_CR16","doi-asserted-by":"publisher","first-page":"2149732","DOI":"10.1080\/13814788.2022.2149732","volume":"29","author":"E Meyers","year":"2023","unstructured":"Meyers E, De Rop L, Deschepper E, Duysburgh E, De Burghgraeve T, Van Ngoc P, Digregorio M, Delogne S, Coen A, De Clercq N, et al. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign. Eur J Gen Pract. 2023;29(2):2149732. https:\/\/doi.org\/10.1080\/13814788.2022.2149732.","journal-title":"Eur J Gen Pract"},{"key":"1939_CR17","doi-asserted-by":"publisher","unstructured":"Meyers E, De Rop L, Gioveni C, Engels F, Coen A, De Burghgraeve T, Digregorio M, Van Ngoc P, De Clercq N, Buret L, et al. Dynamics of SARS-CoV-2 IgG in Nursing Home Residents in Belgium Throughout Three BNT162b2 Vaccination Rounds: 19-Month Follow-Up. Vaccines (Basel). 2025;13(4). https:\/\/doi.org\/10.3390\/vaccines13040409.","DOI":"10.3390\/vaccines13040409"},{"key":"1939_CR18","unstructured":"Belgium COVID-. 19 Epidemiological Situation 2023. https:\/\/lookerstudio.google.com\/embed\/reporting\/c14a5cfc-cab7-4812-848c-0369173148ab\/page\/cUWaB. Accessed on: 1 Sept 2023."},{"issue":"5","key":"1939_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamainternmed.2021.0366","volume":"181","author":"RA Harvey","year":"2021","unstructured":"Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, Meyer WA 3rd;, Kaufman HW, Anderson S, Cohen O, et al. Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. JAMA Intern Med. 2021;181(5):672\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2021.0366.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"1939_CR20","doi-asserted-by":"publisher","first-page":"e01113","DOI":"10.1128\/spectrum.01113-24","volume":"12","author":"E Meyers","year":"2024","unstructured":"Meyers E, Coen A, Padalko E, Cools P. Short- and long-term stability of SARS-CoV-2 antibodies on dried blood spots under different storage conditions. Microbiol Spectr. 2024;12(12):e01113\u201324. https:\/\/doi.org\/10.1128\/spectrum.01113-24.","journal-title":"Microbiol Spectr"},{"key":"1939_CR21","unstructured":"(WHO). W.H.O. WHO International Standard First WHO International Standard for anti-SARS-CoV-2 immunoglobulin. (human) NIBSC code: 20\/136 2020 17\/05\/25."},{"key":"1939_CR22","doi-asserted-by":"publisher","first-page":"105270","DOI":"10.1016\/j.jcv.2022.105270","volume":"155","author":"E Meyers","year":"2022","unstructured":"Meyers E, Coen A, De Sutter A, Padalko E, Callens S, Vandekerckhove L, Witkowski W, Heytens S, Cools P. Diagnostic performance of the SARS-CoV-2 S1RBD IgG ELISA (ImmunoDiagnostics) for the quantitative detection of SARS-CoV-2 antibodies on dried blood spots. J Clin Virol. 2022;155:105270. https:\/\/doi.org\/10.1016\/j.jcv.2022.105270.","journal-title":"J Clin Virol"},{"key":"1939_CR23","first-page":"9597","volume-title":"Vaccination strategy against Covid-19 in Belgium","author":"Superior Health Council","year":"2020","unstructured":"Superior Health Council. Vaccination strategy against Covid-19 in Belgium. Brussels: SHC; 2020. pp. 9597\u2013611."},{"key":"1939_CR24","doi-asserted-by":"crossref","unstructured":"Meyers E, De Rop L, Engels F, Gioveni C, Coen A, De Burghgraeve T, Digregorio M, Van Ngoc P, De Clercq N, Buret L et al. Follow-Up of SARS-CoV-2 Antibody Levels in Belgian Nursing Home Residents and Staff Two, Four and Six Months after Primary Course BNT162b2 Vaccination. Vaccines. 2024;12(8):951.","DOI":"10.3390\/vaccines12080951"},{"issue":"2","key":"1939_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0962280211416299","volume":"24","author":"KED Giacoletti","year":"2011","unstructured":"Giacoletti KED, Heyse J. Using proportion of similar response to evaluate correlates of protection for vaccine efficacy. Stat Methods Med Res. 2011;24(2):273\u201386. https:\/\/doi.org\/10.1177\/0962280211416299.","journal-title":"Stat Methods Med Res"},{"key":"1939_CR26","doi-asserted-by":"publisher","unstructured":"De Rop L, Vercruysse H, Alenus U, Brusselmans J, Callens S, Claeys M, De Coene N, Persyn P, Padalko E, Heytens S, et al. SARS-CoV-2 Seropositivity in Nursing Home Staff and Residents during the First SARS-CoV-2 Wave in Flanders. Belgium Viruses. 2024;16(9). https:\/\/doi.org\/10.3390\/v16091461.","DOI":"10.3390\/v16091461"},{"key":"1939_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S095026882200036X","volume":"150","author":"H Janssens","year":"2022","unstructured":"Janssens H, Heytens S, Meyers E, De Schepper E, De Sutter A, Devleesschauwer B, Formukong A, Keirse S, Padalko E, Geens T, et al. Pre-vaccination SARS-CoV-2 seroprevalence among staff and residents of nursing homes in Flanders (Belgium) in fall 2020. Epidemiol Infect. 2022;150:1\u201325. https:\/\/doi.org\/10.1017\/S095026882200036X.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"1939_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jamda.2023.02.102","volume":"24","author":"A Montoya","year":"2023","unstructured":"Montoya A, Wen K, Travers JL, Rivera-Hernandez M, White E, Mor V, Berry SD. Resident Factors Associated With Breakthrough SARS-CoV-2 Infections. J Am Med Dir Assoc. 2023;24(6):901\u20135. https:\/\/doi.org\/10.1016\/j.jamda.2023.02.102.","journal-title":"J Am Med Dir Assoc"},{"key":"1939_CR29","doi-asserted-by":"publisher","unstructured":"De Maria L, Sponselli S, Caputi A, Stefanizzi P, Pipoli A, Giannelli G, Delvecchio G, Tafuri S, Inchingolo F, Migliore G, et al. SARS-CoV-2 Breakthrough Infections in Health Care Workers: An Italian Retrospective Cohort Study on Characteristics, Clinical Course and Outcomes. J Clin Med. 2023;12(2). https:\/\/doi.org\/10.3390\/jcm12020628.","DOI":"10.3390\/jcm12020628"},{"issue":"5","key":"1939_CR30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/jgs.17773","volume":"70","author":"G Rivasi","year":"2022","unstructured":"Rivasi G, Bulgaresi M, Bandinelli C, Balzi D, Tarantini F, Tognelli S, Lorini C, Buscemi P, Baggiani L, Landini G, et al. Long-term effects of SARS-CoV-2 vaccination in the nursing home setting. J Am Geriatr Soc. 2022;70(5):1336\u201341. https:\/\/doi.org\/10.1111\/jgs.17773.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"1939_CR31","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s40520-021-01959-z","volume":"33","author":"E Benvenuti","year":"2021","unstructured":"Benvenuti E, Rivasi G, Bulgaresi M, Barucci R, Lorini C, Balzi D, Faraone A, Fortini G, Vaccaro G, Del Lungo I, et al. Caring for nursing home residents with COVID-19: a hospital-at-nursing home intermediate care intervention. Aging Clin Exp Res. 2021;33(10):2917\u201324. https:\/\/doi.org\/10.1007\/s40520-021-01959-z.","journal-title":"Aging Clin Exp Res"},{"key":"1939_CR32","doi-asserted-by":"publisher","unstructured":"Dequeker S, Callies M, Vernemmen C, Latour K, Int Panis L, Mahieu R, Noppe L, Savsin M, Duysburgh E. Effect of COVID-19 Vaccination Campaign in Belgian Nursing Homes on COVID-19 Cases, Hospital Admissions, and Deaths among Residents. Viruses. 2022;14(7). https:\/\/doi.org\/10.3390\/v14071359.","DOI":"10.3390\/v14071359"},{"issue":"1","key":"1939_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12916-022-02422-0","volume":"20","author":"SC Open","year":"2022","unstructured":"Open SC, Green A, Curtis H, Hulme W, Williamson E, McDonald H, Bhaskaran K, Rentsch C, Schultze A, MacKenna B, et al. Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. BMC Med. 2022;20(1):243. https:\/\/doi.org\/10.1186\/s12916-022-02422-0.","journal-title":"BMC Med"},{"key":"1939_CR34","doi-asserted-by":"publisher","unstructured":"Walmsley S, Nabipoor M, Lovblom LE, Ravindran R, Colwill K, McGeer A, Dayam RM, Manase D, Gingras AC. On Behalf Of The, S.T. Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination. Vaccines (Basel). 2023;12(1). https:\/\/doi.org\/10.3390\/vaccines12010036.","DOI":"10.3390\/vaccines12010036"},{"key":"1939_CR35","volume-title":"Vaccinatiegraad en epidemiologische impact van de COVID-19-vaccinatiecampagne in Belgi\u00eb. Gegevens tot en met 31 oktober 2021","author":"L Catteau","year":"2021","unstructured":"Catteau L, Stouten vLJ, Billuart V, Hubin M, Haarhuis P, Thomas FW. C. Vaccinatiegraad en epidemiologische impact van de COVID-19-vaccinatiecampagne in Belgi\u00eb. Gegevens tot en met 31 oktober 2021. Brussels, Belgium: Sciensano; 2021. Contract No.: D\/2021\/14.440\/80."},{"issue":"8","key":"1939_CR36","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1002\/jmv.27799","volume":"94","author":"I Torres","year":"2022","unstructured":"Torres I, Bellido-Blasco JB, Gimeno C, Burgos JS, Albert E, Moya-Malo R, Gasco-Laborda JC, Tornero A, Soriano J, Meseguer-Ferrer N, et al. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty(R) COVID-19 vaccination. J Med Virol. 2022;94(8):3776\u201382. https:\/\/doi.org\/10.1002\/jmv.27799.","journal-title":"J Med Virol"},{"issue":"Suppl 2","key":"1939_CR37","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1093\/cid\/ciac562","volume":"75","author":"KM Hatfield","year":"2022","unstructured":"Hatfield KM, Baggs J, Wolford H, Fang M, Sattar AA, Montgomery KS, Jin S, Jernigan J, Pilishvili T. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020-November 2021. Clin Infect Dis. 2022;75(Suppl 2):S147\u201354. https:\/\/doi.org\/10.1093\/cid\/ciac562.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1939_CR38","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamda.2021.12.001","volume":"23","author":"AH Dyer","year":"2022","unstructured":"Dyer AH, Noonan C, McElheron M, Batten I, Reddy C, Connolly E, Pierpoint R, Murray C, Leonard A, Higgins C, et al. Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents. J Am Med Dir Assoc. 2022;23(3):434\u20139. https:\/\/doi.org\/10.1016\/j.jamda.2021.12.001.","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"1939_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.vaccine.2021.11.086","volume":"40","author":"F Helle","year":"2022","unstructured":"Helle F, Moyet J, Demey B, Francois C, Duverlie G, Castelain S, Bloch F, Brochot E. Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status. Vaccine. 2022;40(3):531\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.086.","journal-title":"Vaccine"},{"issue":"1","key":"1939_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12603-021-1713-4","volume":"26","author":"J Moyet","year":"2022","unstructured":"Moyet J, Helle F, Bourdenet G, Joseph C, Gubler B, Deschasse G, Defouilloy I, Slovenski T, Francois C, Liabeuf S, et al. Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities. J Nutr Health Aging. 2022;26(1):57\u201363. https:\/\/doi.org\/10.1007\/s12603-021-1713-4.","journal-title":"J Nutr Health Aging"},{"issue":"1","key":"1939_CR41","doi-asserted-by":"publisher","first-page":"e695","DOI":"10.1093\/cid\/ciab998","volume":"75","author":"P Pannus","year":"2022","unstructured":"Pannus P, Neven KY, De Craeye S, Heyndrickx L, Vande Kerckhove S, Georges D, Michiels J, Francotte A, Van Den Bulcke M, Zrein M, et al. Poor Antibody Response to BioNTech\/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes. Clin Infect Dis. 2022;75(1):e695\u2013704. https:\/\/doi.org\/10.1093\/cid\/ciab998.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1939_CR42","doi-asserted-by":"publisher","first-page":"e0016922","DOI":"10.1128\/msphere.00169-22","volume":"7","author":"EN Gallichotte","year":"2022","unstructured":"Gallichotte EN, Nehring M, Stromberg S, Young MC, Snell A, Daniels J, Pabilonia KL, VandeWoude S, Ehrhart N, Ebel GD. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff. mSphere. 2022;7(4):e0016922. https:\/\/doi.org\/10.1128\/msphere.00169-22.","journal-title":"mSphere"},{"issue":"5","key":"1939_CR43","doi-asserted-by":"publisher","first-page":"e2314757","DOI":"10.1001\/jamanetworkopen.2023.14757","volume":"6","author":"M Gilboa","year":"2023","unstructured":"Gilboa M, Gonen T, Barda N, Cohn S, Indenbaum V, Weiss-Ottolenghi Y, Amit S, Asraf K, Joseph G, Levin T, et al. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel. JAMA Netw Open. 2023;6(5):e2314757\u2013e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14757.","journal-title":"JAMA Netw Open"},{"key":"1939_CR44","doi-asserted-by":"publisher","unstructured":"Cheetham NJ, Kibble M, Wong A, Silverwood RJ, Knuppel A, Williams DM, Hamilton OKL, Lee PH, Bridger Staatz C, Di Gessa G, et al. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies. Elife. 2023;12. https:\/\/doi.org\/10.7554\/eLife.80428.","DOI":"10.7554\/eLife.80428"},{"key":"1939_CR45","doi-asserted-by":"publisher","unstructured":"Fu J, Shen X, Anderson M, Stec M, Petratos T, Cloherty G, Montefiori DC, Landay A, Moy JN. Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Na\u00efve and Convalescent BNT162b2 Recipients. Vaccines (Basel). 2022;10(11). https:\/\/doi.org\/10.3390\/vaccines10111904.","DOI":"10.3390\/vaccines10111904"},{"key":"1939_CR46","doi-asserted-by":"publisher","unstructured":"Suntronwong N, Assawakosri S, Kanokudom S, Yorsaeng R, Auphimai C, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, et al. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination. Diagnostics (Basel). 2022;12(8). https:\/\/doi.org\/10.3390\/diagnostics12081781.","DOI":"10.3390\/diagnostics12081781"},{"issue":"32","key":"1939_CR47","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.063.","journal-title":"Vaccine"},{"issue":"9","key":"1939_CR48","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1002\/jmv.27867","volume":"94","author":"I Torres","year":"2022","unstructured":"Torres I, Gim\u00e9nez E, Albert E, Zulaica J, \u00c1lvarez-Rodr\u00edguez B, Burgos JS, Peir\u00f3 S, Lim\u00f3n R, Vanaclocha H, Rodado C, et al. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty\u00ae COVID-19 vaccine: Looking for correlates of protection. J Med Virol. 2022;94(9):4216\u201323. https:\/\/doi.org\/10.1002\/jmv.27867.","journal-title":"J Med Virol"},{"issue":"5","key":"1939_CR49","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/biomedicines11051247","volume":"11","author":"A Santoro","year":"2023","unstructured":"Santoro A, Capri A, Petrone D, Colavita F, Meschi S, Matusali G, Mizzoni K, Notari S, Agrati C, Goletti D, et al. SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Na\u00efve Hospital Personnel. Biomedicines. 2023;11(5):1247.","journal-title":"Biomedicines"},{"key":"1939_CR50","doi-asserted-by":"publisher","unstructured":"Hertoghs N, Roels S, Br\u00fcckner M, Sadoff J, Banbury BL, Akers NK, Howie B, Robins HS, van Roey GA, Tolboom JTBM, et al. Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial. eBioMedicine. 2025;117(105809). https:\/\/doi.org\/10.1016\/j.ebiom.2025.105809.","DOI":"10.1016\/j.ebiom.2025.105809"},{"key":"1939_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cytogfr.2023.03.001","volume":"70","author":"L Wang","year":"2023","unstructured":"Wang L, M\u00f8hlenberg M, Wang P, Zhou H. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. Cytokine Growth Factor Rev. 2023;70:13\u201325. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.03.001.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"1939_CR52","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jinf.2022.01.044","volume":"84","author":"C Dimeglio","year":"2022","unstructured":"Dimeglio C, Migueres M, Mansuy J-M, Saivin S, Miedoug\u00e9 M, Chapuy-Regaud S, Izopet J. Antibody titers and breakthrough infections with Omicron SARS-CoV-2. J Infect. 2022;84(4):e13\u20135. https:\/\/doi.org\/10.1016\/j.jinf.2022.01.044.","journal-title":"J Infect"},{"issue":"9","key":"1939_CR53","doi-asserted-by":"publisher","first-page":"e2231334","DOI":"10.1001\/jamanetworkopen.2022.31334","volume":"5","author":"K Smoot","year":"2022","unstructured":"Smoot K, Yang J, Tacker DH, Welch S, Khodaverdi M, Kimble W, Wen S, Amjad A, Marsh C, Perrotta PL, et al. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort. JAMA Netw Open. 2022;5(9):e2231334. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31334.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"1939_CR54","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032\u201340. https:\/\/doi.org\/10.1038\/s41591-021-01540-1.","journal-title":"Nat Med"},{"issue":"2","key":"1939_CR55","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.vaccine.2021.12.006","volume":"40","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, Snipe HD, Brown JS, Workman L, Zar HJ, et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2022;40(2):306\u201315. https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.006.","journal-title":"Vaccine"},{"issue":"7","key":"1939_CR56","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1515\/cclm-2022-0082","volume":"60","author":"YBL Hansen","year":"2022","unstructured":"Hansen Y.B.L., Furuta K, Devaraj S, Yilmaz FM, Nordin G. Misleading nomenclature of units of WHO materials used for standardization of SARS COv-2 serology. Clin Chem Lab Med (CCLM). 2022;60(7):e151\u20132. https:\/\/doi.org\/10.1515\/cclm-2022-0082.","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"1","key":"1939_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2022.11.001","volume":"37","author":"Y Abul","year":"2023","unstructured":"Abul Y, Leeder C, Gravenstein S. Epidemiology and Clinical Presentation of COVID-19 in Older Adults. Infect Dis Clin North Am. 2023;37(1):1\u201326. https:\/\/doi.org\/10.1016\/j.idc.2022.11.001.","journal-title":"Infect Dis Clin North Am"}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-026-01939-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-026-01939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-026-01939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:16:10Z","timestamp":1788916570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13690-026-01939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1939"],"URL":"https:\/\/doi.org\/10.1186\/s13690-026-01939-7","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Ghent University Hospital (reference number BC-08719) and conducted according to the principles outlined in the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study. Each participant or their legal representative (e.g., for NHRs with dementia) signed an informed consent form after being informed about the goal of the study and the study procedures.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"198"}}